CSIMarket


Leap Therapeutics inc   (LPTX)
Other Ticker:  
 


 

Leap Therapeutics inc

LPTX's Financial Statements and Analysis



Leap Therapeutics inc increased forth quarter of 2023 net loss per share of $-0.85 compare to net loss per share of $-0.08 recorded in the same quarter a year ago a decrease compare to $-0.51 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.85 $  0 Mill
$-0.77     Unch.    



Leap Therapeutics Inc 's Revenue fell by 0 % in forth quarter of 2023 (Dec 31 2023) year on year, to $0 million and declined by sequentially.


Leap Therapeutics Inc is

More on LPTX's Income Statement



Leap Therapeutics Inc 's in theforth quarter of 2023 recorded net loss of $-12.465 million, an increase from net loss of $-12.102 million in IV. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-13.696 million realized in previous quarter.

More on LPTX's Growth

Leap Therapeutics Inc Inventories
In Dec 31 2023 company's net cash and cash equivalents decreased by $-10 million


Leap Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Leap Therapeutics inc payed $ -2.97 cash per share, on a free-cash flow basis .

Book value grew by 53.22 % sequentially to $4.09 per share.
Tangible Book value grew to $ 4.09 per share from $ 2.67.

Company repurchased 12.28 million shares or 45.49 % in Dec 31 2023.


More on LPTX's Dividends

 Market Capitalization (Millions) 36
 Shares Outstanding (Millions) 15
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -81
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Leap Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Leap Therapeutics inc had negative $ -2.97 cash flow per share, on a free-cash flow basis .

Book value grew by 53.22 % sequentially to $4.09 per share.
Tangible Book value grew to $ 4.09 per share from $ 2.67.

Company repurchased 12.28 million shares or 45.49 % in Dec 31 2023.


More on LPTX's Balance Sheets

 Market Capitalization (Millions) 36
 Shares Outstanding (Millions) 15
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -81
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Leap Therapeutics inc Earnings

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutic...

Leap Therapeutics Inc Faces Short-term Setbacks in Stock Value, But Demonstrates Remarkable Year-to-Date Performance



Leap Therapeutics Inc, a company trading on the NASDAQ, has experienced significant stock fluctuations over the past five trading days, with a decrease of -19.77% in its stock value. However, despite short-term setbacks, the company has demonstrated a remarkable year-to-date performance of 220.93%. Additionally, the stock is currently trading on the NASDAQ at a noteworthy 15.7% above its 52-week average. These figures raise questions about the potential impact of recent financial results on the company's future prospects.
Declining Stock Performance:
The recent decline in Leap Therapeutics Inc's stock value poses concerns for investors. A drop of -19.77% in just five trading days prompts ap...

Leap Therapeutics Inc Posts Narrower Operating Deficit of $-14.662 Million in Q2 2023, Signaling Positive Cost Optimization

Leap Therapeutics Inc, a company in the Major Pharmaceutical Preparations sector, recently published its operating deficit for the second quarter of 2023. The operating deficit for this period was $-14.662 million, which represents an increase compared to the second quarter of 2022, where the operating deficit was $-16.9 million. This is a crucial indicator for the future trajectory of Leap Therapeutics Inc (LPTX).
As an emerging growth business, Leap Therapeutics Inc is focused on building its revenue streams. In order to reach the next chapter of growth, it is essential for the company to operate economically. The recent decrease in operating deficit from $-17.024 million in the second quarter of 2022 ...

Leap Therapeutics Inc witnesses significant surge in outlays during the January-March 2023 quarter

The pharmaceutical industry is a highly competitiv...


Date modified: 2024-03-18T20:55:15+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com